藥局市場規模、佔有率、趨勢分析報告：按產品類型、地區、細分市場預測，2025-2030 年

Pharmacy Market Size, Share & Trends Analysis Report By Product (Prescription, OTC), By Type (Hospital Pharmacy, Retail Pharmacy (Chain, Independent, Others), ePharmacy, Others), By Region, And Segment Forecasts, 2025 - 2030

出版日期: 2025年05月09日 | 出版商:

Grand View Research | 英文 142 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

藥房市場的成長和趨勢：

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年全球藥局市場規模將達到 2.6 兆美元，預測期內的複合年成長率為 7.3%。

成長主要得益於慢性病盛行率的上升、網路藥局服務市場滲透率的提高以及全球零售商進入市場。

主要市場參與企業區域影響力，企業之間建立聯盟，以及日益普及的便利且節省成本的線上藥局服務，預計將進一步推動該市場的成長。不良事件發生率的上升導致成藥需求增加，處方藥市場的成長（主要得益於診斷和影像技術的進步），這些因素很可能在預測期內帶來巨大的成長機會。

用於增強流程和服務交付的先進技術的開發、為製藥行業參與企業開發的各種軟體解決方案的可用性以及促進電子藥房服務成長的智慧型手機設備的廣泛使用也促進了該市場的發展。主要企業之間的合作、線上藥局不斷擴大的數位足跡以及許多專注於加強全球影響力的市場參與企業也在影響著這個市場。

藥房市場報告重點

從產品來看，由於癌症、糖尿病和心血管疾病等慢性疾病的增加，處方箋部分將主導全球製藥業，到 2024 年將佔 80% 以上的收入佔有率。
預計預測期內 OTC 市場將成長最快。
零售藥局部門佔據了藥局產業最大的收益佔有率，這得益於幾家全球零售公司進入藥局業務、主要企業經營的龐大零售藥局網路以及網路零售藥局的成長。
預計在預測期內，電子藥局領域將經歷最快的成長。
北美在全球製藥業佔據主導地位，2024 年的收益佔有率將超過 50%。這歸功於在該地區營運的多家製藥公司以及在多個地點提供服務的大型零售藥局連鎖店，尤其是在美國。

區域市場儀表板
2024 年及 2030 年區域市場佔有率分析
各地區連續生物加工市場：關鍵要點
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 挪威
- 瑞典
- 丹麥
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 泰國
拉丁美洲
- 巴西
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第7章競爭態勢

主要市場參與企業的近期趨勢和影響分析
公司/競爭對手分類
供應商格局
公司簡介
- CVS Health
- Boots Walgreens
- Walmart Inc.
- The Kroger Co.
- Rite Aid Corp.
- MCKESSON CORPORATION
- Well Pharmacy
- Humana
- Matsumotokiyoshi Co., Ltd.
- Apollo Pharmacy
- MedPlusMart.com
- Amazon

簡介目錄圖表

Product Code: GVR-4-68039-701-1

Pharmacy Market Growth & Trends:

The global pharmacy market size is anticipated to reach USD 2.06 trillion by 2030 and is anticipated to expand at a CAGR of 7.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, increasing market penetration of online pharmacy services, and the entry of global retail companies into this market are primarily driving the growth.

Increasing investments by key market participants in improving presence across various regions, collaborations among companies, and rising adoption of online pharmacy services that offer convenience and cost savings are expected to fuel further growth of this market. The growing incident rate of accidents leading to higher demand for OTC drugs and the growth experienced by the prescription medicine segment, primarily due to enhanced diagnostic technologies and imaging techniques, are likely to develop strong growth opportunities over the forecast period.

Adoption of advanced technologies for enhanced processes and service delivery, availability of various software solutions developed for pharmacy industry participants, and increasing ubiquity of smartphone devices, which facilitates the growth of ePharmacy services, also contribute to the advancements experienced by this market. Collaborations among key companies, the growing digital footprint of online pharmacies, and the focus of numerous key market participants on enhancing global presence also influence this market.

Pharmacy Market Report Highlights:

On the basis of products, the prescription segment dominated the global pharmacy industry and accounted for over 80% of the revenue share in 2024, owing to the rising occurrence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases.
The OTC segment is projected to experience the fastest growth over the forecast period.
The retail pharmacy segment held the largest revenue share of the pharmacy industry, owing to the entry of multiple global retail companies in the pharmacy business, a vast network of retail pharmacy stores operated by key players, and the growth experienced by online retail pharmacy.
The ePharmacy segment is anticipated to experience the fastest growth over the forecast period.
North America dominated the global pharmacy industry with a revenue share of more than 50% in 2024, owing to various pharmaceutical manufacturing companies operating in the region and large retail pharmacy chains providing services across multiple locations, especially in the U.S.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product segment
- 1.2.2. Type segment
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Type outlook
- 2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Pharmacy Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Pharmacy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis

Chapter 4. Pharmacy Market: Product Estimates & Trend Analysis

4.1. Product Segment Dashboard
4.2. Pharmacy Market: Product Movement Analysis
4.3. Global Pharmacy Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Prescription
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. OTC
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacy Market: Type Estimates & Trend Analysis

5.1. Type Segment Dashboard
5.2. Pharmacy Market: Type Movement Analysis
5.3. Global Pharmacy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacy
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Retail Pharmacy
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2. Chain
  - 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3. Independent
  - 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.4. Others
  - 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. ePharmacy
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacy Market: Regional Estimates & Trend Analysis

6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Continuous bioprocessing market by Region: Key Takeaways
6.4. North America
- 6.4.1. U.S.
  - 6.4.1.1. Key country dynamics
  - 6.4.1.2. Regulatory framework/ reimbursement structure
  - 6.4.1.3. Competitive scenario
  - 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Canada
  - 6.4.2.1. Key country dynamics
  - 6.4.2.2. Regulatory framework/ reimbursement structure
  - 6.4.2.3. Competitive scenario
  - 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Mexico
  - 6.4.3.1. Key country dynamics
  - 6.4.3.2. Regulatory framework/ reimbursement structure
  - 6.4.3.3. Competitive scenario
  - 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
- 6.5.1. UK
  - 6.5.1.1. Key country dynamics
  - 6.5.1.2. Regulatory framework/ reimbursement structure
  - 6.5.1.3. Competitive scenario
  - 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Germany
  - 6.5.2.1. Key country dynamics
  - 6.5.2.2. Regulatory framework/ reimbursement structure
  - 6.5.2.3. Competitive scenario
  - 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. France
  - 6.5.3.1. Key country dynamics
  - 6.5.3.2. Regulatory framework/ reimbursement structure
  - 6.5.3.3. Competitive scenario
  - 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Italy
  - 6.5.4.1. Key country dynamics
  - 6.5.4.2. Regulatory framework/ reimbursement structure
  - 6.5.4.3. Competitive scenario
  - 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. Spain
  - 6.5.5.1. Key country dynamics
  - 6.5.5.2. Regulatory framework/ reimbursement structure
  - 6.5.5.3. Competitive scenario
  - 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Norway
  - 6.5.6.1. Key country dynamics
  - 6.5.6.2. Regulatory framework/ reimbursement structure
  - 6.5.6.3. Competitive scenario
  - 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.7. Sweden
  - 6.5.7.1. Key country dynamics
  - 6.5.7.2. Regulatory framework/ reimbursement structure
  - 6.5.7.3. Competitive scenario
  - 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.8. Denmark
  - 6.5.8.1. Key country dynamics
  - 6.5.8.2. Regulatory framework/ reimbursement structure
  - 6.5.8.3. Competitive scenario
  - 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
- 6.6.1. Japan
  - 6.6.1.1. Key country dynamics
  - 6.6.1.2. Regulatory framework/ reimbursement structure
  - 6.6.1.3. Competitive scenario
  - 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. China
  - 6.6.2.1. Key country dynamics
  - 6.6.2.2. Regulatory framework/ reimbursement structure
  - 6.6.2.3. Competitive scenario
  - 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. India
  - 6.6.3.1. Key country dynamics
  - 6.6.3.2. Regulatory framework/ reimbursement structure
  - 6.6.3.3. Competitive scenario
  - 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. Australia
  - 6.6.4.1. Key country dynamics
  - 6.6.4.2. Regulatory framework/ reimbursement structure
  - 6.6.4.3. Competitive scenario
  - 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.5. South Korea
  - 6.6.5.1. Key country dynamics
  - 6.6.5.2. Regulatory framework/ reimbursement structure
  - 6.6.5.3. Competitive scenario
  - 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.6. Thailand
  - 6.6.6.1. Key country dynamics
  - 6.6.6.2. Regulatory framework/ reimbursement structure
  - 6.6.6.3. Competitive scenario
  - 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
- 6.7.1. Brazil
  - 6.7.1.1. Key country dynamics
  - 6.7.1.2. Regulatory framework/ reimbursement structure
  - 6.7.1.3. Competitive scenario
  - 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. Argentina
  - 6.7.2.1. Key country dynamics
  - 6.7.2.2. Regulatory framework/ reimbursement structure
  - 6.7.2.3. Competitive scenario
  - 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
- 6.8.1. South Africa
  - 6.8.1.1. Key country dynamics
  - 6.8.1.2. Regulatory framework/ reimbursement structure
  - 6.8.1.3. Competitive scenario
  - 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.2. Saudi Arabia
  - 6.8.2.1. Key country dynamics
  - 6.8.2.2. Regulatory framework/ reimbursement structure
  - 6.8.2.3. Competitive scenario
  - 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.3. UAE
  - 6.8.3.1. Key country dynamics
  - 6.8.3.2. Regulatory framework/ reimbursement structure
  - 6.8.3.3. Competitive scenario
  - 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.4. Kuwait
  - 6.8.4.1. Key country dynamics
  - 6.8.4.2. Regulatory framework/ reimbursement structure
  - 6.8.4.3. Competitive scenario
  - 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
- 7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
- 7.4.1. CVS Health
  - 7.4.1.1. Company overview
  - 7.4.1.2. Financial performance
  - 7.4.1.3. Product benchmarking
  - 7.4.1.4. Strategic initiatives
- 7.4.2. Boots Walgreens
  - 7.4.2.1. Company overview
  - 7.4.2.2. Financial performance
  - 7.4.2.3. Product benchmarking
  - 7.4.2.4. Strategic initiatives
- 7.4.3. Walmart Inc.
  - 7.4.3.1. Company overview
  - 7.4.3.2. Financial performance
  - 7.4.3.3. Product benchmarking
  - 7.4.3.4. Strategic initiatives
- 7.4.4. The Kroger Co.
  - 7.4.4.1. Company overview
  - 7.4.4.2. Financial performance
  - 7.4.4.3. Product benchmarking
  - 7.4.4.4. Strategic initiatives
- 7.4.5. Rite Aid Corp.
  - 7.4.5.1. Company overview
  - 7.4.5.2. Financial performance
  - 7.4.5.3. Product benchmarking
  - 7.4.5.4. Strategic initiatives
- 7.4.6. MCKESSON CORPORATION
  - 7.4.6.1. Company overview
  - 7.4.6.2. Financial performance
  - 7.4.6.3. Product benchmarking
  - 7.4.6.4. Strategic initiatives
- 7.4.7. Well Pharmacy
  - 7.4.7.1. Company overview
  - 7.4.7.2. Financial performance
  - 7.4.7.3. Product benchmarking
  - 7.4.7.4. Strategic initiatives
- 7.4.8. Humana
  - 7.4.8.1. Company overview
  - 7.4.8.2. Financial performance
  - 7.4.8.3. Product benchmarking
  - 7.4.8.4. Strategic initiatives
- 7.4.9. Matsumotokiyoshi Co., Ltd.
  - 7.4.9.1. Company overview
  - 7.4.9.2. Financial performance
  - 7.4.9.3. Product benchmarking
  - 7.4.9.4. Strategic initiatives
- 7.4.10. Apollo Pharmacy
  - 7.4.10.1. Company overview
  - 7.4.10.2. Financial performance
  - 7.4.10.3. Product benchmarking
  - 7.4.10.4. Strategic initiatives
- 7.4.11. MedPlusMart.com
  - 7.4.11.1. Company overview
  - 7.4.11.2. Financial performance
  - 7.4.11.3. Product benchmarking
  - 7.4.11.4. Strategic initiatives
- 7.4.12. Amazon
  - 7.4.12.1. Company overview
  - 7.4.12.2. Financial performance
  - 7.4.12.3. Product benchmarking
  - 7.4.12.4. Strategic initiatives